Regulatory T-cell therapy - Sonoma Biotherapeutics
Alternative Names: Treg cell therapy - Sonoma BiotherapeuticsLatest Information Update: 30 Jul 2024
At a glance
- Originator Sonoma Biotherapeutics
- Class Gene therapies; Regulatory T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Neurodegenerative disorders
- No development reported Autoimmune disorders
Most Recent Events
- 29 Jul 2024 Regulatory T-cell therapy is still in early research phase in Neurodegenerative-disorders in USA (Parenteral) (Sonoma Biotherapeutics pipeline, July 2024)
- 28 Mar 2024 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Mar 2024 No recent reports of development identified for research development in Neurodegenerative-disorders in USA (Parenteral)